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PCI registry, despite higher total healthcare costs, the use of DESwas cost-effective
in patients who underwent 2- and 3-vessel PCI than in single vessel PCI.
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OBJECTIVES: In vitro diagnostic (IVD) has a considerable health economic impact:
60% of patients’ information derives from IVD tests, but IVD makes 1% of the total
health care budget in EU (EDMA, 2010). No cost-effectiveness (CE) analyses are
available onmolecular IVD in allergy; only NICE in the UKmade a CE study IgE IVD
for peanut allergy (PA). Given the impact of PA on quality of life (Qaly), accurate
diagnosis is crucial. 10%of children are considered peanut sensitised, but only 1-2%
is true positive for PA. Subjects with IgE antibodies to allergens Ara h1-2-3 have
high risk of allergic reactions (Astier, 2006). DBPCFC is the gold standard for food-
allergy diagnosis; however it is time-consuming, expensive and might induce se-
vere reactions (Nicolau, 2010). IVD can give clinicians a tool to decide the need of
DBPCFC (Sastre, 2010); is IVD CE compared to DBPCFC in suspected PA children in
EU, US and Japan?METHODS: Data was collected at Stockholm’s Sach=s Children’s
hospital (Nilsson, 2011) and from published literature. A 5-year Markov simulation
model comparing IVD (ImmunoCap® - allergens f13, Ara h 1- 2-3-8-9) with DBPCFC
was developed with Tree AgePro®, to analyse CE for IVD and the incremental cost
per Qaly in suspected PA children. The sensitivity and specificity of each diagnos-
tics determines the percentage of patients true-allergic, false-allergic, true-healthy
and false-healthy. BaseCase® was used to interactively visualize results. Results
are presented from the health care perspective; care giver indirect costs are in-
cluded in a sensitivity analysis. RESULTS: IgE IVD is CE and cost saving for children
with suspected PA in multiple countries compared to golden standard DBPCFC.
CONCLUSIONS: IVD is a CE alternative to DBPCFC in selected patients in multiple
countries. DBPCFCmight be replaced in selected cases, still being useful in subjects
with conflicting immunological/clinical results (Codreanu, 2011).
PMD34
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OBJECTIVES:Wound complications following surgical procedures are a significant
cost burden to the health care system and have been identified as one of the
hospital-acquired infections not reimbursed by payers. Surgical site infections
have been associated with both an increased hospital stay of 9.58 extra days and
$38,656 in additional medical charges, and postoperative dehiscence can add as
much as 9.42 extra days, resulting in $40,323 in additional charges. A health eco-
nomicmodel was developed to demonstrate potential cost savings associatedwith
using closed incision management (CIM*) to apply negative pressure wound ther-
apy (NPWT) over clean closed surgical incisions in patients treated for an open
fracture of the tibia and fibula. METHODS: The hypothetical economic model ap-
plied national cost dollars to clinical outcomes of the Stannard et al randomized
controlled trial (RCT) usingNPWT†over closed incisions. National cost data (Thom-
son Reuters custom report) were selected using the diagnosis codes related to the
population of patients within the Stannard et al RCT, which were open fracture of
the tibia and fibula with complications such as infection and dehiscence (ICD9
79.36). The infection rates (10%, 14/141 patients NPWT and 19%, 23/122 patients
Control [standard of care], p0.049) and dehiscence rates (8.6%, 12/141 NPWT and
16.5%, 20/122 Control, p0.044) were calculated from the Stannard et al RCT and
were applied to a hypothetical 100 patient population (50 CIM and 50 Control).
RESULTS: Reduced infection and dehiscence rates in this patient population re-
sulted in potential per patient cost savings of $5338 for infection and $1586 for
dehiscence with CIM. CONCLUSIONS: These findings illustrate the potential cost
effectiveness of CIM over closed incisions of high-risk fractures. *Prevena™ Inci-
sion Management System and †V.A.C. Therapy; KCI USA, Inc., San Antonio, TX,
USA
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Current available methods in Mexico for blood group typing are made through a
tube serological antigen/antibody reaction (TST) but has limitations due to the lack
of blood weak antigens detection that generate incomplete information on blood
group phenotype and potential recipient alloimmunization that can cause life
threatening transfusion-related reactions as acute lung injury and hemolytic
reactions. OBJECTIVES: To develop an economic model based in Mexican Institute
of Social Security (IMSS) resource payments to evaluate the cost-effectiveness of
ANDCK versus TST for the determination of blood erythrocyte variants in Mexico.
METHODS: A two branch decision tree model was developed to evaluate and com-
pare the cost-effectiveness in Mexican pesos (MxP) of ANDCK and TST for the
determination of blood erythrocyte variants. The effectivenessmeasure was blood
group typing errors rate obtained from published clinical trials. Resource use and
cost were obtained from expert interviews and IMSS published data respectively.
The model estimated cost per patient and incremental cost-effectiveness ratios
(ICER). Costs and effectiveness do not were discounted. A deterministic sensitivity
analysis was also performed. RESULTS: The rate of blood group typing errors was
0.07% for ANDCK group and 0.17% for TST group. Cost per patientwas always lower
with ANDCK ($2,340.00 MxP) than TST ($3,921.21 MxP) showing that ANDCK was
the dominant alternative. Sensitivity analysis shows model robustness and con-
firms ANDCK as dominant alternative. CONCLUSIONS: Our results show that
ANDCK is cost-effective for the determination of blood erythrocyte variants in
Mexico and should be considered by clinicians and decision makers as a favorable
option for the determination of blood group typing in order to avoid life threatening
transfusion-related reactions.
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OBJECTIVES: The objective of the study was to evaluate the economic impact of
adding the use of chlorhexidine gluconate (CHG) impregnated sponge dressings to
Canadianhospitals’ standard infection prevention routine. The current standard of
care for catheter insertion in Canada involves hand hygiene, skin preparation and
transparent film dressings. The aim of this study was to determine whether the
addition of CHG impregnated sponge dressings to catheter insertion procedurewas
cost-effective. METHODS: The economic model was populated with clinical and
economic data obtained from peer-reviewed literature along with case-costing
data froma large Canadian hospital network. One and twoway sensitivity analyses
were conducted on economic and clinical parameters to ensure robustness.
RESULTS: Based on model calculations using a hypothetical hospital with 400 in-
patient beds and 20 intensive care unit beds, the use of CHG dressings would
reduce the number of CLABSIs from 107 to 43 annually, and would reduce the
number of local site infections from 430 to 258 annually. The model demonstrates
cost savings through the reduction of CLABSI and local site infections as well as
through decreased nursing costs. Themodel establishes that the use of CHG dress-
ings has the potential to provide $869, 867.49 of net cost savings in one hospital per
year. CONCLUSIONS: The use of chlorhexidine gluconate impregnated sponge
dressings for central venous and arterial catheter insertion sites proves to be a
cost-effective intervention in Canadian hospitals.
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OBJECTIVES: The aim of this study is to evaluate the cost-effectiveness of CT cor-
onary angiography (CTCA) and myocardial SPECT for ischemic heart disease in
patients with chest pain.METHODS:We assessed cost-effective of CTCA andmyo-
cardial SPECT for patients with intermediate risk with pre-test likelihood of 10-90.
The model was analyzed by using diagnosis accuracy and QALY. The model using
diagnosis accuracy used the number of patients accurately diagnosed among 1000
persons as the effect, and reflecting only themedical expenses for tests as the cost.
In the model using QALY, a decision tree was developed and the time horizon was
1 year. Utility weights were calculated using questionnaires for each case from
general population. Costs were calculated through analysis of Health Insurance
Review & Assessment Service claim data and transition probabilities were esti-
mated from retrospective cohort data. Analyses were conducted from the Health-
care system perspectives. RESULTS: In the model using diagnosis accuracy, CTCA
appeared to be more effective (224.41 correct diagnosis) and even less expensive
(US$58,819 per 1,000 persons) thanmyocardial SPECT proposed to be the dominate
alternative. In themodel using QALY, CTCA showedmore effective (0.00040QALYs)
and less cost (US$465) than myocardial SPECT. Sensitivity analysis was performed
for transition probabilities, utilityweights and costs. The results of sensitivity anal-
ysis were robust. In subgroup analysis, myocardial SPECT showed cost-effective in
patients with pre-test likelihood of 30-60. CONCLUSIONS: In conclusion, cost-ef-
fective analysis between CTCA andmyocardial SPECT indicated that CTCAwas the
cost-effective test for both models using diagnosis accuracy and the one using
QALY in patients with intermediate risk with pre-test likelihood of 10-90.
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OBJECTIVES: The cost implications of adopting portablemonitoring devices for the
diagnosis of obstructive sleep apnea (OSA) are largely unknown.We conducted an
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